Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Financial Bull 3X Shares ETF
FAS
US Stock MarketDetailed Quotes
Nanoviricides (NNVC)
- 1.300
- +0.060+4.84%
Close May 1 15:59 ET
- 1.300
- 0.0000.00%
Post 20:01 ET
28.07MMarket Cap-2.65P/E (TTM)
1.330High1.210Low303.56KVolume1.240Open1.240Prev Close390.18KTurnover1.55%Turnover RatioLossP/E (Static)21.60MShares2.23052wk High2.53P/B25.51MFloat Cap0.85052wk Low--Dividend TTM19.63MShs Float262.500Historical High--Div Yield TTM9.68%Range %0.850Historical Low1.285Avg Price1Lot Size
NNVC Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
NNVC Orderflow
Unit: --
NNVC Orderflow Trend
IntradayDayWeekMonth
No Data
Nanoviricides (NNVC) News
NanoViricides Measles Virus Treatment Granted FDA Orphan Status
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 Is Here to Help Patients and Control Spread, Says NanoViricides
NanoViricides Seeks FDA's Rare Pediatric Disease Designation for Antiviral Candidate NV-387 - ICYMI | NYSE-A:NNVC
Small Caps Wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X...
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Small Cap Wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium...
Nanoviricides (NNVC) Stock Forum
$Nanoviricides (NNVC.US)$ NanoViricides Files Application For Rare Pediatric Disease Drug Designation For NV-387 As Treatment For Measles With US FDA Office Of Orphan Products Development
Benzinga
2m
NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "...
Benzinga
2m
NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "...
2
$Nanoviricides (NNVC.US)$
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
by ACCESS Newswire
Follow
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced toda...
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
by ACCESS Newswire
Follow
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced toda...
2
$Nanoviricides (NNVC.US)$ give me something my little friend we need too by Friday
$Nanoviricides (NNVC.US)$ nice little swing right here gang
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)